KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Net Margin (2019 - 2025)

Royalty Pharma's Net Margin history spans 7 years, with the latest figure at 57.22% for Q4 2025.

  • For Q4 2025, Net Margin rose 90.0% year-over-year to 57.22%; the TTM value through Dec 2025 reached 55.68%, down 311.0%, while the annual FY2025 figure was 55.68%, 311.0% down from the prior year.
  • Net Margin for Q4 2025 was 57.22% at Royalty Pharma, down from 72.91% in the prior quarter.
  • Across five years, Net Margin topped out at 145.37% in Q2 2021 and bottomed at 107.83% in Q4 2022.
  • The 5-year median for Net Margin is 47.38% (2024), against an average of 50.24%.
  • The largest annual shift saw Net Margin plummeted -11715bps in 2022 before it soared 22821bps in 2023.
  • A 5-year view of Net Margin shows it stood at 9.32% in 2021, then plummeted by -1257bps to 107.83% in 2022, then surged by 212bps to 120.39% in 2023, then plummeted by -53bps to 56.32% in 2024, then grew by 2bps to 57.22% in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Net Margin are 57.22% (Q4 2025), 72.91% (Q3 2025), and 15.66% (Q2 2025).